375 related articles for article (PubMed ID: 28576179)
1. Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy.
Dan T; Williams NL
Surg Oncol Clin N Am; 2017 Jul; 26(3):393-403. PubMed ID: 28576179
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.
Abbas G; Danish A; Krasna MJ
Surg Oncol Clin N Am; 2016 Jul; 25(3):553-66. PubMed ID: 27261915
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.
Chang JY; Bezjak A; Mornex F;
J Thorac Oncol; 2015 Apr; 10(4):577-85. PubMed ID: 25514807
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
Boily G; Filion É; Rakovich G; Kopek N; Tremblay L; Samson B; Goulet S; Roy I;
J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
[TBL] [Abstract][Full Text] [Related]
7. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
Shultz DB; Diehn M; Loo BW
Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
9. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?
Mirimanoff RO
Chin Clin Oncol; 2015 Dec; 4(4):42. PubMed ID: 26730754
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.
Loganadane G; Martinetti F; Mercier O; Krhili S; Riet FG; Mbagui R; To H; Le Péchoux C; Levy A
Cancer Treat Rev; 2016 Nov; 50():240-246. PubMed ID: 27768919
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
[TBL] [Abstract][Full Text] [Related]
13. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
Ashworth A; Kong W; Owen T; Hanna TP; Brundage M
Radiother Oncol; 2024 May; 194():110153. PubMed ID: 38364940
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
15. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
[TBL] [Abstract][Full Text] [Related]
16. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons.
Louie AV; Palma DA; Dahele M; Rodrigues GB; Senan S
Radiother Oncol; 2015 Feb; 114(2):138-47. PubMed ID: 25497873
[TBL] [Abstract][Full Text] [Related]
17. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
18. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.
Louie AV; van Werkhoven E; Chen H; Smit EF; Paul MA; Widder J; Groen HJ; van den Borne BE; De Jaeger K; Slotman BJ; Senan S
Radiother Oncol; 2015 Oct; 117(1):44-8. PubMed ID: 26492839
[TBL] [Abstract][Full Text] [Related]
19. SBRT effective for inoperable early-stage lung cancer.
Cancer Discov; 2014 Dec; 4(12):OF2. PubMed ID: 25477119
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes.
Iyengar P; Timmerman RD
J Natl Compr Canc Netw; 2012 Dec; 10(12):1514-20. PubMed ID: 23221789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]